Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average - What's Next?

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.18 and traded as high as $16.40. Assembly Biosciences shares last traded at $16.07, with a volume of 23,075 shares trading hands.

Analyst Ratings Changes

A number of research firms have recently commented on ASMB. Guggenheim began coverage on Assembly Biosciences in a research note on Tuesday, March 25th. They issued a "buy" rating and a $31.00 target price on the stock. HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a research note on Monday, March 24th. Finally, Wall Street Zen lowered shares of Assembly Biosciences from a "buy" rating to a "hold" rating in a research note on Monday, March 24th.

Assembly Biosciences Stock Performance

The firm has a 50-day moving average of $11.97 and a 200-day moving average of $13.18. The firm has a market capitalization of $131.76 million, a P/E ratio of -2.77 and a beta of 0.55.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.01) by $0.84. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The firm had revenue of $9.42 million for the quarter, compared to the consensus estimate of $7.41 million. On average, research analysts forecast that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. Gilead Sciences Inc. purchased a new stake in Assembly Biosciences during the 4th quarter valued at $34,865,000. Renaissance Technologies LLC grew its holdings in shares of Assembly Biosciences by 44.3% in the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock worth $1,495,000 after acquiring an additional 29,087 shares during the period. Peapod Lane Capital LLC purchased a new stake in Assembly Biosciences during the fourth quarter valued at $994,000. B Group Inc. bought a new position in Assembly Biosciences in the fourth quarter valued at about $799,000. Finally, Monimus Capital Management LP bought a new position in Assembly Biosciences in the fourth quarter valued at about $664,000. Hedge funds and other institutional investors own 19.92% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.